{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:59:52Z","timestamp":1785207592765,"version":"3.55.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejim.2025.106693","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T04:19:04Z","timestamp":1767413944000},"page":"106693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reassessing the safety signal: Dihydropyridine calcium channel blockers in the era of quadruple therapy for heart failure. Author's reply"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5509-8867","authenticated-orcid":false,"given":"Mauro","family":"Gori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-7435","authenticated-orcid":false,"given":"Luca","family":"Fazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-7923","authenticated-orcid":false,"given":"Renata","family":"De Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.106693_bib0001","doi-asserted-by":"crossref","unstructured":"Wang B., Huang J., Chen Z. Reassessing the safety signal: dihydropyridine calcium channel blockers in the era of quadruple therapy for heart failure. Eur J Intern Med, Volume 0, Issue 0, 106646. DOI:10.1016\/j.ejim.2025.106646.","DOI":"10.1016\/j.ejim.2025.106646"},{"key":"10.1016\/j.ejim.2025.106693_bib0002","article-title":"Effects of calcium channel blockers on GDMT prescription and outcomes according to ejection fraction: IN-HF real world data","author":"Gori","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"18","key":"10.1016\/j.ejim.2025.106693_bib0003","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejim.2025.106693_bib0004","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jchf.2025.01.014","article-title":"Overcoming the risk-treatment paradox: prescribing GDMT for severe heart failure","volume":"13","author":"Greene","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.ejim.2025.106693_bib0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/eurjpc\/zwac004","article-title":"Associations between calcium channel blocker therapy and mortality in heart failure with preserved ejection fraction","volume":"29","author":"Wang","year":"2022","journal-title":"Eur J Prev Cardiol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525005709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525005709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:27:38Z","timestamp":1785205658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525005709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":5,"alternative-id":["S0953620525005709"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106693","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reassessing the safety signal: Dihydropyridine calcium channel blockers in the era of quadruple therapy for heart failure. Author's reply","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106693"}}